Botulinum Toxin Treatment of Neuropathic Pain

Semin Neurol. 2016 Feb;36(1):73-83. doi: 10.1055/s-0036-1571953. Epub 2016 Feb 11.

Abstract

Neuropathic pain (NP), a common form of human pain, often poorly responds to analgesic medications. In this review the authors discuss the pathophysiology and conventional treatment of neuropathic pain and provide evidenced-based statements on the efficacy of botulinum neurotoxins (BoNTs) in this form of pain. The level of efficacy for BoNT treatment in each category of NP is defined according to the published guidelines of the American Academy of Neurology. The data indicate that BoNT treatment (most of the literature is with onabotulinumtoxinA) is effective (level A evidence) in postherpetic neuralgia and trigeminal neuralgia. It is probably effective (level B) in posttraumatic neuralgia and painful diabetic neuropathy. The data on complex regional pain syndrome, carpal tunnel syndrome, occipital neuralgia, and phantom limb pain are preliminary and await conduction of randomized, blinded clinical trials. Much remains to be learned about the most-effective dosage and technique of injection, optimum dilutions, and differences among BoNTs in the treatment of neuropathic pain.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Acetylcholine Release Inhibitors / administration & dosage
  • Analgesics / administration & dosage*
  • Botulinum Toxins / administration & dosage
  • Botulinum Toxins, Type A / administration & dosage*
  • Diabetic Neuropathies / diagnosis
  • Diabetic Neuropathies / drug therapy
  • Diabetic Neuropathies / physiopathology
  • Female
  • Humans
  • Middle Aged
  • Neuralgia / diagnosis*
  • Neuralgia / drug therapy*
  • Neuralgia / physiopathology
  • Treatment Outcome

Substances

  • Acetylcholine Release Inhibitors
  • Analgesics
  • Botulinum Toxins
  • Botulinum Toxins, Type A